But there are other ways of harnessing the immune system. So you'll see clinical trials looking at vaccines and adjuncts to add to immunotherapy. You'll even see clinical trials looking at CAR T-cell therapy and other cellular immune therapies. We've learned that some of the signaling pathwa...
The major advancement in clinical trials is the switch from late-stage palliative treatment to early preoperative neoadjuvant therapy, as more TNBC cases are discovered at an early stage. Immunotherapy is also highlighted with additional alternatives for advanced or metastasized TNBC, such as...
Why are clinical trials important? Clinical trials are a vital part of the process in finding new cancer treatments and ultimately a cure for cancer. Without these research studies, many of the advances we see today in cancer detection, treatment and prevention would never have happened. ...
Dr Nathanson on Next Steps for Identifying Novel Resistance Mechanisms in Breast Cancer Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia A Close Look at Clinical Trials in Oncology and Beyond: State of Affairs and Industry Progress Dr Kaddoura on Challenges Integrating...
trials aim to reclassify a certain traditional disease type based on potential therapeutic biomarkers. Recruited patients are assigned to different molecular subgroups and matched with corresponding drugs. The platform trials aim to continuously screen biomarkers and drugs for a certain disease. The ...
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care View More Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials View More Cases & Conversations™: Integrating Novel Approaches...
Several Trop-2-targeted ADCs, such as Sacituzumab Govitecan (SG) and Datopotamab Deruxtecan (Dato-DXd), have demonstrated significant antitumor activity in clinical trials for both triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative (HR /HER...
manageable toxicity in patients with heavily pretreated metastatic TNBC. As a dynamic and ongoing platform for novel targeted regimens, FUTURE can enable efficient testing of potential new drug–biomarker combinations in the context of subtyping, generating clues for further validation in expansion trials...
We Need More Black Patients In Multiple Myeloma Clinical Trials Malignant hematologist Craig Cole, MD exposes the health disparity for Black people with multiple myeloma and encourages researchers, with specific tips on how to do so, to include more Black people in trials for MM therapies. ...
We also summarized the recent progress in vaccination strategy, immunotherapy involving immune checkpoint inhibitors, and biomarker detection for various cancers based on nanoplatforms. At last, we gave a detailed picture of the current nanomedicines in clinical trials and their possible success along ...